The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs). The current rule for starting treatment of HIV infection is to combine members from different classes of anti-HIV drugs, such as 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either a PI or a nonnucleoside reverse transcriptase inhibitor (NNRTI). However, these combinations can be complicated and difficult to take, can cause a number of side effects, and may become ineffective. Combinations that are simpler, better tolerated, and more effective are needed. Because PIs can cause long-term side effects and because HIV can become resistant to many of them at the same time, anti-HIV combination treatments that do not use PIs are being tested.
Inclusion Criteria Patients may be eligible for this study if they: * Are HIV-positive. * Have a viral load of at least 400 copies/ml within 90 days prior to study entry. * Are at least 16 years old. * Weigh at least 40 kg. * Have a negative pregnancy test within 48 hours before starting study drugs, if female and able to have children. * Agree to use 2 effective methods of birth control while taking, and for 3 months after stopping, the study medications. * Provide written consent of a parent or guardian, if under 18 years of age. Exclusion Criteria Patients will not be eligible for this study if they: * Have taken anti-HIV drugs in the past. * Are allergic to any of the study drugs or ingredients. * Are pregnant or breast-feeding. * Have taken any of the following drugs within 14 days prior to study entry: amiodarone, astemizole, bepridil, cisapride, ergot or ergot derivatives, systemic itraconazole, systemic ketoconazole, midazolam, propoxyphene, quinidine, rifampin, terfenadine, thalidomide, triazolam, or St. John's wort. * Have taken drugs that influence the immune system, HIV or other vaccines, or investigational drugs within 30 days prior to study entry. Prednisone at a dose of 10 mg or less daily is allowed. * Have taken drugs or been hospitalized for serious infections or medical illnesses within 14 days prior to study entry. * Have growths or tumors that require drug therapy. * Have Pneumocystis carinii pneumonia that is not clinically stable and whose treatment is not completed at least 7 days prior to study entry. * Have infections or medical illnesses that are not under control or that have not received complete treatment before study entry. * Have any condition that, in the opinion of the investigator, would prevent them from properly participating in the study. * Abuse drugs or alcohol. * This study has been updated to exclude patients who are receiving systemic itraconazole and rifabutin.